Method for surgical treatment of bladder cancer in patients with end-stage renal disease on renal replacement therapy with program hemodialysis simultaneously with treatment and prevention of purulent pyelonephritis. Review of clinical cases

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Bladder cancer (BC) is one of the most common malignancies in the world and ranks 7th in the structure of oncopathology in men and 17th in women. Patients on renal replacement therapy (RRT) have been shown to have a more aggressive tumor and often a more advanced stage of the disease. In most cases, the disease is asymptomatic at an early stage and difficult to screen. As a rule, clinical manifestations and diagnosis occur at the muscle-invasive stage, where organ-preserving treatment is not possible.

Description of the clinical cases. From 2021 to 2023, 2 patients with muscle-invasive bladder cancer with end-stage renal disease (ESRD), who were on RRT with program hemodialysis, underwent surgery at the City Clinical Hospital № 52. All patients underwent laparoscopic bilateral nephroureterectomy, cystoprostatvesiculectomy, ad bloc ureterectomy.

Results. All patients underwent minimally invasive surgical treatment. There were no complications in the early and late operative periods, and there were no lethal cases. According to the results of histological examination in all patients, the kidney tissue has sclerotic changes and thinned urothelium without signs of tumor growth, mono- or bilateral apostematous pyelonephritis. The first patient had muscle-invasive urothelial bladder cancer pT2b N0. The second patient has metastases in the lymph nodes of the small pelvis. Also as an accidental finding, prostate cancer pT2N0 Gleason 6 (3+3) was detected. During the follow-up period at the outpatient settings, no data on the progression of the oncological process were received.

Conclusion. On the example of these clinical cases, it can be convinced that the radical treatment of muscle-invasive bladder cancer in patients with ESRD is possible in combination with the removal of a purulent-septic focus, and in some cases it can be a prevention of purulent-septic complications. However, in the treatment of these diseases, it is necessary to apply a multimodal approach to develop optimal methods for diagnosis and treatment.

Full Text

Restricted Access

About the authors

Ruslan N. Trushkin

City Clinical Hospital № 52 of the Moscow Healthcare Department, Department of Urology

Author for correspondence.
Email: uro52@mail.ru
ORCID iD: 0000-0002-3108-0539

Dr.Sci. (Med.), Head of the Urology Department, City Clinical Hospital № 52 of the Moscow Healthcare Department

Russian Federation, Moscow

Aleksey G. Martov

D.D. Pletnev City Clinical Hospital of the Moscow Healthcare Department, Department of Urology (minimally invasive methods for diagnosing and treating urological diseases); A.I. Burnazyan Medical and Biological University of Innovations and Continuous Education nof the FMBA of Russia Medical Scientific and Educational Center of the Lomonosov Moscow State University

Email: martovalex@mail.ru
ORCID iD: 0000-0001-6324-6110

Corresponding Member of the Russian Academy of Sciences, Dr.Sci. (Med.), Professor, Head of the Department of Urology and Andrology, A.I. Burnazyan Biomedical University of Innovation and Continuing Education of the FMBA of Russia; Head of the Department of Urology (minimally invasive methods for diagnosing and treating urological diseases), D.D. Pletnev City Clinical Hospital of the Moscow Healthcare Department, Leading Researcher at the Medical Research and Education Center of the Lomonosov Moscow State University

Russian Federation, Moscow; Moscow; Moscow

Sergey A. Sokolov

City Clinical Hospital № 52 of the Moscow Healthcare Department, Department of Urology

Email: sergey.sokolow@mail.ru
ORCID iD: 0009-0004-7016-2360

Urologist at the Urology Department, City Clinical Hospital № 52 of the Moscow Healthcare Department

Russian Federation, Moscow

Teimur K. Isaev

City Clinical Hospital № 52 of the Moscow Healthcare Department, Department of Urology

Email: dr.isaev@mail.ru
ORCID iD: 0000-0003-3462-8616

Cand.Sci. (Med.), Urologist at the Urology Department, City Clinical Hospital № 52 of the Moscow Healthcare Department

Russian Federation, Moscow

Nikolay E. Shcheglov

City Clinical Hospital № 52 of the Moscow Healthcare Department, Department of Urology

Email: nickshch@mail.ru
ORCID iD: 0000-0002-1018-8460

Cand.Sci. (Med.), Urologist at the Urology Department, City Clinical Hospital № 52 of the Moscow Healthcare Department

Russian Federation, Moscow

Petr P. Teikhrib

City Clinical Hospital № 52 of the Moscow Healthcare Department, Department of Urology

Email: teihrib_petr@mail.ru
ORCID iD: 0009-0001-0636-0571

Urologist at the Urology Department, City Clinical Hospital № 52 of the Moscow Healthcare Department

Russian Federation, Moscow

References

  1. Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424.
  2. Lenis A.T., Lec P.M., Chamie K. Bladder Cancer: A Review. JAMA. 2020;324(19):1980–91. doi: 10.1001/jama.2020.17598.
  3. Martinez Rodriguez R.H., Buisan Rueda O., Ibarz L. Bladder cancer: Present and future. Med. Clin. (Barc). 2017;149(10):449–55. English, Spanish. doi: 10.1016/j.medcli.2017.06.009.
  4. Choyke P.L. Radiologic evaluation of hematuria: guidelines from the American College of Radiology’s appropriateness criteria. Am. Fam. Physician. 2008;78:347.
  5. Kurth K.H., et al. Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Int. J. Urol. 1995;2(Suppl. 2):8–22.
  6. Huang L., et al. The Diagnostic Value of MR Imaging in Differentiating T Staging of Bladder Cancer: A Meta-Analysis. Radiology. 2018;286:502.
  7. Chinnadurai R., Flanagan E., Jayson G.C., et al. Cancer patterns and association with mortality and renal outcomes in non-dialysis dependent chronic kidney disease: a matched cohort study. BMC. Nephrol. 2019;20:380.
  8. Nitta K. 2018 Annual Dialysis Data Report, JSDT Renal Data Registry. Nihon Toseki Igakkai Zasshi. 2020;52(12):679–754. doi: 10.4009/jsdt.52.679.
  9. Гумилевский Б.Ю., 2009.
  10. Sato Y., Kondo T., Takagi T., et al. Treatment strategy for bladder cancer in patients on hemodialysis: a clinical review of 28 cases. Int. Urol. Nephrol. 2016;48(4):503–9. doi: 10.1007/s11255-015-1199-2.
  11. Shariat S.F., et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J. Urol. 2006;176:2414.
  12. Mertens L.S., et al. Prostate sparing cystectomy for bladder cancer: 20-year single center experience. J. Urol. 2014;191:1250.

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Cystoscopy

Download (201KB)
3. Fig. 2. Remote organ complex as a single block (ad bloc)

Download (315KB)
4. Fig. 3. MRI of the pelvis

Download (90KB)
5. Fig. 4. Remote organ complex as a single block (ad bloc)

Download (287KB)

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies